Document Classification

Section Type: RESULTS

Text: Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review : 7. 8 versus 3. 2 months, respectively ; hazard ratio = 0. 45 (95 % confidence interval 0. 38-0. 54) ; log-rank P < 0. 0001 ; central review : 11. 0 versus 4. 1 months, respectively ; hazard ratio = 0. 38 (95 % confidence interval 0. 31-0. 48) ; log-rank P < 0. 0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, [corrected] and irrespective of age.